- Home
- DOW vs WAT Comparison
DOW vs WAT Comparison
Compare DOW & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOW
- WAT
- Stock Information
- Founded
- DOW 1897
- WAT 1958
- Country
- DOW United States
- WAT United States
- Employees
- DOW N/A
- WAT N/A
- Industry
- DOW Major Chemicals
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- DOW Industrials
- WAT Industrials
- Exchange
- DOW Nasdaq
- WAT Nasdaq
- Market Cap
- DOW 16.3B
- WAT 17.4B
- IPO Year
- DOW N/A
- WAT 1995
- Fundamental
- Price
- DOW $22.31
- WAT $387.37
- Analyst Decision
- DOW Hold
- WAT Buy
- Analyst Count
- DOW 15
- WAT 13
- Target Price
- DOW $27.13
- WAT $379.00
- AVG Volume (30 Days)
- DOW 13.4M
- WAT 637.6K
- Earning Date
- DOW 10-23-2025
- WAT 11-04-2025
- Dividend Yield
- DOW 6.28%
- WAT N/A
- EPS Growth
- DOW N/A
- WAT 3.82
- EPS
- DOW N/A
- WAT 10.88
- Revenue
- DOW $40,913,000,000.00
- WAT $3,105,638,000.00
- Revenue This Year
- DOW N/A
- WAT $7.12
- Revenue Next Year
- DOW $2.54
- WAT $6.22
- P/E Ratio
- DOW N/A
- WAT $35.50
- Revenue Growth
- DOW N/A
- WAT 6.90
- 52 Week Low
- DOW $20.40
- WAT $275.05
- 52 Week High
- DOW $46.98
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- DOW 43.52
- WAT 77.28
- Support Level
- DOW $21.70
- WAT $340.09
- Resistance Level
- DOW $22.75
- WAT $382.02
- Average True Range (ATR)
- DOW 0.76
- WAT 10.44
- MACD
- DOW -0.16
- WAT 2.22
- Stochastic Oscillator
- DOW 14.14
- WAT 99.09
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.